

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr FAMPYRA™

fampridine

Extended-Release Tablet, 10 mg, Oral

Potassium Channel Blocker

Biogen Canada Inc.
3250 Bloor Street West, East Tower, Suite 1200
Toronto, ON, M8X 2X9

Date of Initial Authorization:
FEB 8, 2012

Date of Revision:
January 24, 2022

Submission Control Number: 249412

© Biogen [2012]. All rights reserved.

RECENT MAJOR LABEL CHANGES

--	--

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment.....	5
4.4 Administration.....	5
4.5 Missed Dose	6
5 OVERDOSAGE	7
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	8
7 WARNINGS AND PRECAUTIONS	8
7.1 Special Populations.....	12
7.1.1 Pregnant Women.....	12
7.1.2 Breast-feeding.....	12
7.1.3 Pediatrics.....	12
7.1.4 Geriatrics	13
8 ADVERSE REACTIONS	13
8.1 Adverse Reaction Overview.....	13
8.2 Clinical Trial Adverse Reactions.....	13
8.2.1 Clinical Trial Adverse Reactions – Pediatrics	15
8.3 Less Common Clinical Trial Adverse Reactions	15

8.3.1	Less Common Clinical Trial Adverse Reactions – Pediatrics	17
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	17
8.5	Post-Market Adverse Reactions.....	17
9	DRUG INTERACTIONS	18
9.2	Drug Interactions Overview.....	18
9.3	Drug-Behavioural Interactions.....	18
9.4	Drug-Drug Interactions	18
9.5	Drug-food Interactions.....	20
9.6	Drug-herb Interactions.....	21
9.7	Drug-laboratory Test Interactions.....	21
10	CLINICAL PHARMACOLOGY	21
10.1	Mechanism of Action.....	21
10.2	Pharmacodynamics	21
10.3	Pharmacokinetics.....	21
11	STORAGE, STABILITY AND DISPOSAL	23
12	SPECIAL HANDLING INSTRUCTIONS	24
PART II: SCIENTIFIC INFORMATION		24
13	PHARMACEUTICAL INFORMATION.....	24
14	CLINICAL TRIALS.....	24
14.1	Trial Design and Study Demographics	24
14.2	Study Results	25
15	MICROBIOLOGY	28
16	NON-CLINICAL TOXICOLOGY	28
PATIENT MEDICATION INFORMATION		31

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

FAMPYRA (fampridine) extended-release tablets are indicated for:

- the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5-7). The initial prescription should be for no more than 4 weeks, and assessment for improvement in walking should be carried out within that timeframe (see 4 DOSAGE AND ADMINISTRATION).

FAMPYRA should only be prescribed by (or following consultation with) clinicians who are experienced in the management of multiple sclerosis and who are knowledgeable of the efficacy and safety profile of FAMPYRA and are able to discuss the benefits/risks with patients.

1.1 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics: Renal function should be checked in elderly patients before starting treatment with FAMPYRA and monitored regularly. Use in patients with moderate or severe renal impairment is contraindicated (see 2 CONTRAINDICATIONS; 7.1 WARNINGS AND PRECAUTIONS Special Populations).

2 CONTRAINDICATIONS

FAMPYRA (fampridine) extended-release tablets are contraindicated in:

- Patients who are hypersensitive to FAMPYRA or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with fampridine.
- Patients taking concurrent compounded 4-aminopyridine or other forms of fampridine.
- Patients with moderate or severe renal impairment (creatinine clearance <50mL/min) (see 7 WARNINGS AND PRECAUTIONS, Renal Impairment).
- Patients with a prior history or current presentation of seizure (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Seizure Risk).
- Patients taking medicinal products that are inhibitors of the renal Organic Cation Transporter 2 (OCT2), such as cimetidine and quinidine (see 9.4 DRUG INTERACTIONS,

Drug-Drug Interactions, ORGANIC CATION TRANSPORTER 2 (OCT2)).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

The maximum recommended dosage of FAMPYRA is one 10 mg tablet twice daily and should not be exceeded. Take doses approximately 12 hours apart.

There is no evidence of additional benefit at doses greater than 10 mg twice daily. Adverse reactions, including seizures, and discontinuations because of adverse reactions were more frequent at higher doses.

4.2 Recommended Dose and Dosage Adjustment

- Pediatrics (<18 years of age): Health Canada has not authorized an indication for pediatric use.
- Adults: The recommended dose of FAMPYRA (fampridine) extended-release tablets is one 10 mg tablet twice daily. One 10 mg tablet should be taken in the morning and one 10 mg tablet should be taken in the evening. The doses should be taken 12 hours apart.
- Geriatrics: Renal function should be determined in elderly patients before starting treatment with FAMPYRA. Monitoring renal function to detect any renal impairment is recommended in elderly patients (see 10.3 CLINICAL PHARMACOLOGY, Clinical Pharmacokinetics, Special Populations and Conditions).
- Hepatic Impairment: No dose adjustment is required for patients with hepatic impairment.
- Renal Impairment: FAMPYRA is contraindicated in patients with moderate or severe renal impairment (Creatinine Clearance <50 mL/min) (see 2 CONTRAINDICATIONS). Determining renal function before treatment, and regular monitoring during treatment, is recommended in all patients.

4.4 Administration

Tablets should only be taken by swallowing whole with a glass of water. Doses should be taken without food.

Patients should be advised to not divide, crush, dissolve, suck or chew the tablet because broken tablets can release too much of the drug at one time and increase the risk of seizure adverse events. Patients should also be advised not to take an extra dose if a dose is missed, due to the increased risk of seizure adverse events.

- Starting FAMPYRA Treatment: Initial assessment of benefit

- The initial prescription for FAMPYRA should be for no more than 4 weeks of therapy as clinical benefits should generally be identified within 4 weeks after starting FAMPYRA.
- The assessment for evaluation of improvement should be conducted prior to starting treatment and again within 4 weeks.
- FAMPYRA should be discontinued if benefit is not reported by patient.
- Ongoing confirmation of positive benefit/risk profile
 - Physicians should continue to actively review the benefit/risk of FAMPYRA for the individual patient, to ensure continued positive benefit/risk.

In all cases, FAMPYRA should be discontinued if patients no longer report benefit, or if seizure occurs.

Patients should be informed of the following:

- FAMPYRA should be taken exactly as prescribed, one 10 mg tablet in the morning and one 10 mg tablet in the evening. Doses should be taken 12 hours apart.
- Do not take an extra dose after missing a dose.
- There is a dose-dependent risk of seizure. FAMPYRA must be discontinued if they experience a seizure.
- Renal impairment increases plasma concentration of fampridine, which may lead to an increased risk of seizure. Advise patients that co-administration of certain drugs or medicinal products, such as beta blockers (carvedilol, pindolol, propranolol), procainamide, metformin, ranitidine and varenicline, can impact renal function.
- The assessment of improvement in walking should be done within 4 weeks of starting FAMPYRA treatment. If there is no benefit to the patient seen within that time frame, treatment should be stopped.
- Patients should be informed of the signs and symptoms of a serious allergic reaction (e.g. itching, swelling of the face, tongue, throat, difficulty breathing, rash etc.). Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms.

4.5 Missed Dose

The dosing regimen of one tablet in the morning and one tablet in the evening taken 12 hours apart should always be followed. Patients should be advised to not take an extra dose if a dose is missed.

No additional benefit was demonstrated at doses greater than 10 mg twice daily and adverse events and discontinuations were more frequent at higher doses. In particular, the risk of seizure may increase with doses greater than 10 mg twice daily.

5 OVERDOSAGE

Acute symptoms of overdose with FAMPYRA were consistent with central nervous system excitation and included confusion, tremulousness, diaphoresis, seizure, and amnesia. Central nervous system side effects at high doses of 4-aminopyridine include confusion, seizures, status epilepticus, involuntary and choreoathetoid movements. Other side effects at high doses include cases of cardiac arrhythmias (for example, supraventricular tachycardia and bradycardia) and ventricular tachycardia as a consequence of potential QT prolongation. Reports of hypertension have also been received.

Several cases of overdose are found in the scientific literature in which various formulations of fampridine were used, resulting in adverse events including seizure, confusion, tremulousness, diaphoresis and amnesia. In some instances, patients developed status epilepticus, requiring intensive supportive care and were responsive to standard therapy for seizures.

Three cases of overdose were reported in controlled clinical trials with FAMPYRA (fampridine) extended-release tablets, involving two MS patients. The first patient took six times the currently recommended dose (60 mg) and was taken to the emergency room with altered mental state. The second patient took 40 mg doses on two separate occasions. In the first instance, the patient experienced a complex partial seizure and, in the second instance, a period of confusion was reported. Both patients recovered by the following day without sequelae.

Patients with repeated seizure activity should be treated with benzodiazepine, phenytoin, or other appropriate acute anti-seizure therapy.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
oral	Extended-release tablet, 10 mg of fampridine per tablet	Tablet: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose Film-coat: hypromellose, macrogol/PEG 400, titanium dioxide

FAMPYRA (fampridine) extended-release tablets are film-coated, white to off-white, biconvex, oval shaped, non-scored tablets with flat edge, debossed with 'A10' on one side containing 10 mg fampridine. Bottles containing 14 tablets and a silica gel desiccant. Four bottles in a carton.

7 WARNINGS AND PRECAUTIONS

General

FAMPYRA (fampridine) should be used under the supervision of a clinician experienced in the treatment of multiple sclerosis and familiar with the safety and efficacy of FAMPYRA.

Recommended dose should not be exceeded due to an increased risk of seizure (see 4.2 DOSAGE AND ADMINISTRATION). FAMPYRA (fampridine) extended-release tablets should not be administered at doses higher than the recommended dose of 10 mg twice daily. One 10 mg tablet should be taken in the morning and one 10 mg tablet should be taken in the evening. The doses should be taken 12 hours apart. Treatment with fampridine increases seizure risk. A dose-dependent increase in risk of seizures has been observed in clinical studies with FAMPYRA at doses above the recommended dose of 10 mg taken twice daily. In open label extension trials in MS patients, the incidence of seizures during treatment with FAMPYRA 15 mg twice daily (1.7/100 patient years) was over 4 times higher than the incidence during treatment with 10 mg twice daily (0.4/100 patient years) (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Seizure Risk).

Renal impairment and certain concomitant medications are among the factors that can result in increased fampridine plasma levels, and therefore result in increased risk of seizure (see 2 CONTRAINDICATIONS; 7 WARNINGS AND PRECAUTIONS, Renal).

Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with fampridine. In several cases, these reactions occurred after the first dose. These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, and urticaria. Patients should be informed of the signs

and symptoms of a serious allergic reaction (e.g. itching, swelling of the face, tongue, throat, difficulty breathing, rash etc.). Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms.

Concurrent treatment with other forms of 4-aminopyridine (4-AP, fampridine) is contraindicated since the active ingredient is the same (see 2 CONTRAINDICATIONS). Patients should discontinue use of any product containing 4-aminopyridine prior to initiating treatment with FAMPYRA in order to reduce the potential for dose-related adverse reactions.

Carcinogenesis and Mutagenesis

See 16 NON-CLINICAL TOXICOLOGY.

Cardiovascular

Cardiac Conduction Disorders:

FAMPYRA is a potassium channel blocker and, therefore, should be administered with caution to patients with cardiovascular symptoms of rhythm and sinoatrial or atrioventricular conduction cardiac disorders (these effects are seen in overdose). There is limited safety information in patients with cardiovascular disease as they were excluded from the clinical trials.

Driving and Operating Machinery

Since dizziness or fatigue may occur with the use of this drug, sensitive patients should be cautioned against activities requiring mental alertness and physical coordination until their response to the drug has been well-established. Exercise caution when driving or operating a vehicle or potentially dangerous machinery.

Genitourinary

A higher incidence of urinary tract infections (UTI) was reported with FAMPYRA (12%) than with placebo (8%), during controlled clinical trials. The underlying mechanism is not fully understood but may involve the effect of fampridine on the sensory and or motor innervation of the bladder. Adverse events of UTI were frequently reported based on symptoms of UTI without confirmation from urinalysis or culture results. Reported UTIs are usually moderate and transient.

Immune

- Hypersensitivity Reactions:

Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed in patients treated with fampridine. In several cases, these reactions occurred after the first dose. These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, and urticaria. Patients should be informed of the signs and symptoms of a serious allergic reaction (e.g. itching, swelling of the face, tongue, throat, difficulty breathing, rash, etc.). Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms.

- Infections and Infestations:

In clinical studies low white blood cell counts were seen in 2.1% of FAMPYRA patients versus 1.9% of patients on placebo. Infections were seen in the clinical studies as stated below (Table 1). An increased infection rate and impairment of the immune response cannot be excluded.

Table 1 - Infections and Infestations

	Placebo Controlled Studies MS-F202/ MS-F203/ MS-F204		
	Placebo (n=238)	FAMPYRA 10 mg BID (n=400)	TEAEs ^a) with Incidence ≥1% in FAMPYRA vs Placebo
Infections and Infestations	59 (24.8%)	124 (31.0%)	6.2%
Gastroenteritis viral	4 (1.7%)	6 (1.5%)	-
Influenza	0 (0%)	9 (2.3%)	1.5%
Nasopharyngitis	4 (1.7%)	14 (3.5%)	1.8%
Pneumonia	1 (0.4%)	4 (1.0%)	-
Sinusitis	8 (3.4%)	6 (1.5%)	-
Upper respiratory tract infection	15 (6.3%)	20 (5.0%)	-
Urinary tract infection	20 (8.4%)	48 (12.0%)	3.6%
Viral infection	1 (0.4%)	6 (1.5%)	1.1%

^a TEAEs – Treatment Emergent Adverse Events

Monitoring and Laboratory Tests

Clearance of fampridine is decreased in patients with renal impairment and is significantly correlated with creatinine clearance. Therefore, determining renal function before treatment and its regular monitoring during treatment is recommended in all patients who may be at risk of reduced renal function (see 2 CONTRAINDICATIONS; 7 WARNINGS AND PRECAUTIONS, Renal and Special Populations; and 10 CLINICAL PHARMACOLOGY).

Neurologic

- Dizziness and Balance Disorder:

The increased incidence of dizziness, vertigo and balance disorder seen with FAMPYRA may result in an increased risk of falls. Patients who are using walking aids should continue to use these aids as needed.

- Exacerbation of Trigeminal Neuralgia:

Exacerbation of Trigeminal neuralgia has been reported in MS patients with history of

trigeminal neuralgia treated with fampridine during postmarketing experience (see ADVERSE REACTIONS, Post market Adverse Drug Reactions). In the majority of cases, onset was within 1 month of initiating treatment with FAMPYRA and symptoms improved or resolved following discontinuation of FAMPYRA, with or without pharmacological treatment of the trigeminal neuralgia. Some patients that received pharmacological treatment for adverse events of worsening trigeminal neuralgia required higher doses of previously effective treatments to manage symptoms.

- Seizure Risk:

A dose-dependent increase in risk of seizures has been observed in clinical studies with FAMPYRA at doses above the recommended dose. The recommended daily dose of FAMPYRA, 10 mg twice daily, taken 12 hours apart, should not be exceeded.

Treatment in patients with a prior history or current presentation of seizure is contraindicated.

Prior to starting FAMPYRA, all patients should be assessed for their risk of seizure, by taking a full patient history. Patients who are considered by the physician to be at high risk of seizure should be excluded from treatment (see 2 CONTRAINDICATIONS).

The risk of seizures is also increased with renal impairment, due to reduced clearance of fampridine (see 10.3 CLINICAL PHARMACOLOGY, Special Populations and Conditions, Renal Insufficiency). Therefore, assessment of the risk of seizure should also include assessment of renal function prior to initiating treatment with FAMPYRA. Treatment of patients with mild, moderate or severe renal impairment (creatinine clearance ≤ 30 <50 mL/min) is contraindicated (see 2 CONTRAINDICATIONS).

FAMPYRA should be administered with caution in the presence of factors which may lower seizure threshold.

FAMPYRA should be discontinued immediately in patients who experience a seizure while on treatment and not restarted.

Published epidemiological studies indicate that the MS population has a higher background prevalence of seizures than the general population (2 to 4% vs. 0.5 to 1%). This rate increases with age and progressive disease. In the MS population, the background incidence rate of first seizures has been reported to be in the range of 0.2 to 0.6 cases per 100 person-years. The seizure incidence observed during over 1,200 person-years of exposure in open-label treatment of MS patients with FAMPYRA tablets 10 mg twice daily is consistent with this expected background rate (0.41 cases per 100 person-years).

In placebo-controlled studies in MS, the incidence of seizure was not higher in the patients treated with fampridine 10 mg twice daily than in the placebo-treated patients (1/532 [0.19%] versus 1/249 [0.4%], respectively).

As seizures have been seen with the compounded form of fampridine and the immediate release formulations, the clinical trials were designed to exclude patients with a history of seizure or epileptiform activity. The safety data from the controlled trials has shown that at the recommended therapeutic dose (fampridine 10 mg twice daily), the risk of seizure is no

higher than the placebo group.

Renal

FAMPYRA is primarily excreted unchanged through the kidneys. Patients with renal impairment have higher plasma concentrations (see 10.3 CLINICAL PHARMACOLOGY, Special Populations and Conditions, Renal Insufficiency), which are associated with increased adverse drug reactions, in particular neurological effects. Because patients with renal impairment would require a dose lower than 10 mg twice daily and dosage strengths less than 10 mg are not available, FAMPYRA is contraindicated in patients with ~~mild~~, moderate and severe renal impairment [Creatinine Clearance (CrCl) <50 mL/min] (see 2 CONTRAINDICATIONS).

Determining renal function before treatment, and regular monitoring during treatment, is recommended in all patients. Creatinine clearance can be estimated using the Cockcroft-Gault formula (multiply by 0.85 for women):

$$\text{CrCl} = \frac{(140 - \text{age}) \times \text{weight}(\text{kg})}{\text{SerumCr}(\text{mg} / \text{dl}) \times 72}$$

Caution is required when FAMPYRA is prescribed concurrently with drugs or medicinal products that can significantly impact renal function. These include substrates of OCT2, such as beta blockers (carvedilol, pindolol, propranolol), procainamide, metformin, ranitidine and varenicline. Inhibitors of OCT2 (including cimetidine and quinidine are contraindicated (see 9 DRUG INTERACTIONS; 2 CONTRAINDICATIONS).

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled studies of FAMPYRA in pregnant women. The use of FAMPYRA during pregnancy should only be considered if the potential benefit to the mother justifies the potential risk to the fetus.

Administration of fampridine to animals during pregnancy resulted in decreased offspring viability and growth at doses 6.8 times the maximum recommended human dose (MRHD) of 20 mg/day (see 16 NON-CLINICAL TOXICOLOGY).

7.1.2 Breast-feeding

It is not known whether fampridine is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from fampridine, FAMPYRA is not recommended during breast feeding.

7.1.3 Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

7.1.4 Geriatrics

Because elderly patients are more likely to have decreased renal function, renal function should be determined in elderly patients before starting treatment with FAMPYRA and monitored regularly (see 10.3 CLINICAL PHARMACOLOGY, Pharmacokinetics).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The most serious and/or most frequently occurring adverse reactions may be described as follows: The most commonly reported adverse reactions in adults are urinary tract infection (12%), insomnia (8.8%), dizziness (7.3%), headache (7.0%), balance disorder (4.8%), anxiety (1.5%), tremor (1.0%), paraesthesia (4.0%), and asthenia (6.8%). Adverse reactions identified are mostly neurological and relate to nervous system excitation, including seizures. This is consistent with fampridine's pharmacological activity (see 10 CLINICAL PHARMACOLOGY)

Adverse reactions identified are mostly neurological and relate to nervous system excitation, including seizure, insomnia, anxiety, balance disorder, dizziness, paraesthesia, tremor, headache and asthenia. This is consistent with fampridine's pharmacological activity. The highest incidence of adverse reactions identified from placebo-controlled trials in multiple sclerosis patients with FAMPYRA given at the recommended dose, are reported as urinary tract infection (in approximately 12% of patients, and 8% in patients given placebo).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Table 2 lists treatment emergent adverse events that occurred during active treatment in $\geq 1\%$ of FAMPYRA-treated MS patients and more frequent compared to placebo in controlled clinical trials.

Table 2 - Treatment-Emergent Adverse Events with an incidence of $\geq 1\%$ of FAMPYRA treated MS patients and at $\geq 1\%$ higher rate than for placebo

Adverse Event	Placebo N=238	FAMPYRA 10 mg twice daily N= 400
Gastrointestinal disorders		
Constipation	5 (2.1%)	13 (3.3%)
Dyspepsia	2 (0.8%)	8 (2.0%)

Adverse Event	Placebo N=238	FAMPYRA 10 mg twice daily N= 400
Nausea	6 (2.5%)	28 (7.0%)
Vomiting	1 (0.4%)	7 (1.8%)
General disorders and administration site conditions		
Aesthenia	9 (3.8%)	27 (6.8%)
Infections and infestations		
Influenza	0 (0%)	9 (2.3%)
Urinary tract infection	20 (8.4%)	48 (12.0%)
Viral infection	1 (0.4%)	6 (1.5%)
Investigations		
White blood cell count decreased	0 (0%)	4 (1.0%)
Metabolism and nutrition disorders		
Hypertriglyceridemia	0 (0%)	4 (1.0%)
Musculoskeletal and connective tissue disorders		
Back Pain	5 (2.1%)	20 (5.0%)
Nervous system disorders		
Balance Disorder	3 (1.3%)	19 (4.8%)
Dizziness	10 (4.2%)	29 (7.3%)
Headache	9 (3.8%)	28 (7.0%)
Paraesthesia	6 (2.5%)	16 (4.0%)
Tremor	0 (0%)	4 (1.0%)
Psychiatric disorders		
Anxiety	1 (0.4%)	6 (1.5%)
Insomnia	9 (3.8%)	35 (8.8%)
Respiratory, thoracic and mediastinal disorders		
Dyspnoea	0 (0%)	4 (1.0%)
Nasopharyngitis	4(1.7%)	14 (3.5%)
Pharyngolaryngeal pain	2 (0.8%)	8 (2.0%)
Skin and subcutaneous tissue disorders		

Adverse Event	Placebo N=238	FAMPYRA 10 mg twice daily N= 400
Pruritus	1 (0.4%)	6 (1.5%)

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

8.3 Less Common Clinical Trial Adverse Reactions

The following is a list of treatment-emergent adverse events reported by patients treated with fampridine any dose and any formulation in the safety population (n=1,510). This population includes patients receiving fampridine during clinical pharmacology studies, placebo-controlled studies in patients with multiple sclerosis, placebo-controlled studies in patients with spinal cord injury and uncontrolled studies.

Events that have already been included in Table 2 have been excluded. Although the events reported occurred during treatment with fampridine, they were not necessarily caused by fampridine.

Blood and lymphatic system disorders: anaemia, lymph node pain, leukopenia, neutropenia

Cardiovascular: palpitations, tachycardia, atrioventricular block first degree, bundle branch block right, chest pain, coronary artery disease, ventricular extrasystoles, ventricular hypertrophy, bundle branch block left, dilatation ventricular

Ear and labyrinth disorders: tinnitus, vertigo, deafness bilateral, ear pain

Endocrine Disorders: goitre, thyroid cyst

Eye Disorders: vision blurred, visual disturbance, blepharospasm, blindness, conjunctivitis, diplopia, eye haemorrhage, eye movement disorder, lacrimation increased, ocular hyperaemia, photopsia, scotoma, eyelid ptosis

Gastrointestinal disorders: abdominal discomfort, dry mouth, flatulence, stomach discomfort, toothache, abdominal hernia, abdominal pain lower, abdominal tenderness, dysphagia, epigastric discomfort, gastritis, haemorrhoidal haemorrhage, hypoesthesia oral, irritable bowel syndrome, colitis, haematemesis

General disorders and administrative site conditions: chest discomfort, chest pain, chills, feeling hot, gait disturbance, influenza like illness, irritability, catheter related complication, cyst, gravitational oedema, injection site erythema, pitting oedema, suprapubic pain, tenderness

Immune System Disorders: hypersensitivity, seasonal allergy

Infections and Infestations: bronchitis, cystitis, ear infection, fungal infection, herpes simplex, tooth abscess, vulvovaginal mycotic infection, bacterial infection, candidiasis, escherichia urinary tract infection, eye infection, folliculitis, herpes virus infection, infection, labyrinthitis, laryngitis, localised infection, oral candidiasis, otitis externa, pharyngitis, pharyngitis streptococcal, rhinitis, sepsis, skin infection, subcutaneous abscess, tooth infection, abscess oral, bacterial pyelonephritis, clostridial infection, gingival abscess, paronychia, vaginal infection

Injury Poisoning and procedural complications: back injury, joint sprain, muscle strain, procedural pain, skin laceration, thermal burn, arthropod bite, arthropod sting, corneal abrasion, epicondylitis, eschar, fibula fracture, hand fracture, joint injury, laceration, ligament injury, neck injury, patella fracture, skeletal injury, sunburn, tendon injury, tooth fracture, wrist fracture, fracture, ligament sprain

Investigations: blood cholesterol increased, blood creatine phosphokinase increased, blood triglycerides increased, body temperature increased, white blood cell count increased, aspartate aminotransferase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood phosphorus increased, blood potassium decreased, blood potassium increased, blood urea increased, cardiac murmur, carotid bruit, crystal urine present, electrocardiogram T wave inversion, electrocardiogram abnormal, full blood count abnormal, heart rate decreased, heart rate increased, heart rate irregular, hepatic enzyme increased, lymphocyte count decreased, monocyte count decreased, neutrophil count decreased, platelet count decreased, red blood cell count decreased, red blood cell count increased, red blood cells urine, red blood cells urine positive, weight increased, white blood cells urine, blood cholesterol abnormal, right ventricular systolic pressure increased, thyroxine increased, urine cytology abnormal

Metabolic and nutritional disorders: decreased appetite, hypercholesterolaemia, diabetes mellitus, hypokalaemia, polydipsia

Musculoskeletal and connective tissue disorders: bursitis, chest wall pain, muscle tightness, musculoskeletal discomfort, osteoporosis, bone pain, cervical spasm, groin pain, joint instability, limb discomfort, muscle twitching, musculoskeletal chest pain, osteoarthritis, osteopenia, pain in jaw, sensation of heaviness, trigger finger

Neoplasms benign, malignant and unspecified (including cysts and polyps): breast cancer, uterine leiomyoma, lentigo

Nervous system disorders: migraine, neuropathic pain, somnolence, trigeminal neuralgia, amnesia, dysaesthesia, dysgeusia, lethargy, Lhermitte's sign, motor dysfunction, myoclonus, neuralgia, nystagmus, peroneal nerve palsy, sciatica, sinus headache, syncope, anticholinergic syndrome, head titubation

Psychiatric disorders: abnormal dreams, confusional state, nervousness, sleep disorder, hallucination, panic attack, paranoia

Renal and urinary disorders: dysuria, micturition urgency, urinary incontinence, urinary retention, bladder spasm, nephrolithiasis, nocturia, polyuria, pyuria, terminal dribbling, urinary hesitation

Reproductive system and breast disorders: menorrhagia

Respiratory, thoracic and mediastinal disorders: nasal congestion, sinus congestion, asthma, atelectasis, epistaxis, hiccups, pharyngeal erythema, rhinorrhea, wheezing, nasal dryness, sinus disorder

Skin and subcutaneous tissue disorders: blister, ecchymosis, hyperhidrosis, skin ulcer, alopecia, cold sweat, dry skin, ingrown nail, livedo reticularis, purpura, rash macular, scab, skin lesion, drug eruption, hypotrichosis, skin fissures, telangiectasia

Vascular disorders: hot flush, hypertension, peripheral coldness, deep vein thrombosis, flushing, haematoma, hypotension, phlebitis, thrombosis

Seizures: Cases of seizure were reported infrequently during controlled clinical trials and open label extension studies with fampridine (5/532, 0.9 % and 5/660, 0.76%, respectively). Most of these incidences were associated with uncontrolled overdose, high systemic doses, or high plasma levels of fampridine (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Seizure Risk).

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics

No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

No information is currently available.

8.5 Post-Market Adverse Reactions

The following adverse reactions have been identified during post marketing experience with fampridine: seizures, exacerbations of trigeminal neuralgia (TN) in patients with a history of TN (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Exacerbation of Trigeminal Neuralgia), vertigo and hypersensitivity reactions (including anaphylactic/anaphylactoid reactions such as swollen tongue and swollen throat (pharyngeal edema) (see 2 CONTRAINDICATIONS; 7 WARNINGS AND PRECAUTIONS, Immune, Hypersensitivity Reactions). For the majority of cases of anaphylaxis, a relationship to fampridine could not be excluded.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In a placebo-controlled study (218MS305), with 635 patients included in the safety population (placebo: N=319; FAMPYRA: N=316), the safety profile observed was consistent with the

known safety profile of FAMPYRA and no new safety concerns were identified (see 14 CLINICAL TRIALS).

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter medications.

FAMPYRA is contraindicated in patients taking medicinal products that are inhibitors of the renal Organic Cation Transporter 2 (OCT2), such as cimetidine and quinidine (see 2 CONTRAINDICATIONS).

Because fampridine is actively excreted unchanged by the kidneys; there is the potential for interactions with other drugs that are renally excreted (see 10.3 CLINICAL PHARMACOLOGY, Pharmacokinetics).

No pharmacokinetic drug interactions were observed between FAMPYRA (fampridine) and interferon or baclofen. There was evidence of direct inhibition of CYP2E1 by fampridine at 30 μ M (approximately 12% inhibition) which is approximately 100 times the average plasma fampridine concentration measured for the 10mg tablet.

9.3 Drug-Behavioural Interactions

The influence of behavioural risks on adverse events or treatment outcomes related to FAMPYRA has not been established.

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 3 - Established or Potential Drug-Drug Interactions

Proper / Common name	Source of Evidence	Effect	Clinical comment
CYP2E1 substrates/inhibitors e.g disulfiram, chlorzoxazone	T	<i>In vitro</i> data with human liver microsomes showed that fampridine was not a direct or time-dependent inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5 at concentrations up to 30 µM. There was evidence of direct inhibition of CYP2E1 by fampridine at 30 µM (approximately 12 % inhibition), which is approximately 100 times the average plasma fampridine concentration measured for the 10 mg FAMPYRA tablet.	<i>In vitro</i> data with human liver microsomes showed that fampridine was not a direct or time-dependent inhibitor of CYP enzymes.
Potential for Fampridine to Affect Other Drugs	T	Other <i>in vitro</i> studies with cultured human hepatocytes with 0.025 µM, 0.25 µM, 2.5 µM and 25 µM fampridine had little or no effect on CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2E1 or CYP3A4/5 enzyme activities.	The potential for 4-aminopyridine to induce human hepatocytes at therapeutic concentrations is remote.
P-glycoprotein Transporter	T	<i>In vitro</i> , fampridine is not a substrate or an inhibitor for the P-glycoprotein transporter.	The pharmacokinetics of FAMPYRA are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and fampridine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter.

Proper / Common name	Source of Evidence	Effect	Clinical comment
Organic Cation Transporter 2 (OCT2) substrates/inhibitors e.g. cimetidine, beta blockers (carvedilol, pindolol, propranolol), procainamide, metformin, ranitidine and varenicline	T, CT	Fampridine is eliminated mainly via the kidneys with active renal secretion accounting for about 60% of elimination. <i>In vitro</i> studies have shown that the Organic Cation Transporter (OCT2) is the main transporter responsible for the active secretion of fampridine. Therefore, the concomitant use of fampridine with medicinal products that are inhibitors of OCT2 for example, cimetidine and quinidine, is contraindicated and concomitant use of fampridine with medicinal products that are substrates of OCT2 for example, beta blockers (carvedilol, pindolol, propranolol), procainamide, metformin, ranitidine and varenicline is cautioned (see CONTRAINDICATIONS; WARNINGS AND PRECAUTIONS, Renal). <u>Cimetidine</u> : In a single-dose clinical study, the OCT2 inhibitor cimetidine 400 mg every 6 hours and fampridine 10 mg single dose were concurrently administered to 23 healthy volunteers. The test-reference ratio for AUC _{0-∞} was 125.1% (90% CI: 120.5%, 129.8%) due to a reduction in apparent clearance of fampridine (CL/F). This increase in systemic exposure is not expected to be clinically meaningful.	The concomitant use of fampridine with medicinal products that are inhibitors of OCT2.

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

9.5 Drug-food Interactions

FAMPYRA should be taken without food. When fampridine tablets is taken with food, C_{max} increases by 15-23%, therefore there is a clear relationship between C_{max} and dose related adverse reactions. It is recommended to take Fampyra without food. (see 4 DOSAGE AND ADMINISTRATION, 10 CLINICAL PHARMACOLOGY, Pharmacokinetics).

9.6 Drug-herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

The mechanism by which fampridine exerts its therapeutic effect has not been fully elucidated. Fampridine (4-aminopyridine, 4-AP) is a broad spectrum potassium channel blocker. In animal tissue preparations, fampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Fampridine blocks multiple potassium channels. When the axon is demyelinated the internodal membrane and its ion channels become exposed to larger electrical transients during the passage of an action potential. Leakage of ionic current through the potassium channel, under these conditions, then contributes to impairment of action potential conduction through the axon. In animal tissue preparations, 4-AP has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels. Fampridine is thought to reduce the leakage of ionic current through these channels and enhance action potential formation in demyelinated axons.

Based on studies in animals, by blocking potassium channels, FAMPYRA is thought to reduce the leakage of ionic current through these channels and enhance action potential formation in demyelinated axons. It is thought that by enhancing action potential formation, more impulses might be conducted in the central nervous system.

10.2 Pharmacodynamics

In animal studies on demyelinated nerve fibers, (dal)fampridine has shown enhanced action potential conduction at concentrations of $\sim 1 \mu\text{M}$ (94 ng/mL) with IC₅₀ values in the range of 2-3 μM (188-282 ng/mL) recorded. In contrast, the action potential of myelinated axons shows little or no sensitivity to (dal)fampridine at concentration below 100 μM .

(Dal)fampridine does not prolong the QTc interval and does not have a clinically important effect on QRS duration.

10.3 Pharmacokinetics

Fampyra is characterized by linear (dose-proportional) pharmacokinetics with a terminal elimination half-life of approximately 6 hours. The maximum plasma concentration (C_{max}) and, to a smaller extent, area under the plasma concentration-time curve (AUC) increase proportionately with dose. There is no evidence of clinically relevant accumulation of

fampridine taken at the recommended dose in patients with full renal function. In patients with renal impairment, accumulation occurs relative to the degree of impairment.

Table 4 - Summary of Fampridine Pharmacokinetic Parameters in adult patient population

	C_{max} (ng/mL)	T_{max} (h)	t_½ (h)	AUC_{0-∞} (h*ng/mL)	CL/F (L/h)	Vd (L/kg)
Single dose mean (one 10 mg tablet twice daily)	17.3 – 21.6	3 – 4	5.2 – 6.5	201.9 – 284.8	35.5 – 50.9	2.6

Absorption:

Orally administered fampridine is rapidly and completely absorbed from the gastrointestinal tract. Absolute bioavailability of extended-release FAMPYRA tablets has not been assessed, but relative bioavailability is 96% when compared to an aqueous oral solution. The extended release tablet delays absorption of fampridine relative to the solution formulation manifested by slower rise to a lower peak concentration (C_{max}), with no effect on the extent of absorption (AUC).

When fampridine tablets are taken with food, the reduction in the area under the plasma concentration-time curve (AUC_{0-∞}) of fampridine is approximately 2-7% (10 mg dose). The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy.

Distribution:

Fampridine is largely unbound to plasma proteins (97–99%). The apparent volume of distribution is 2.6 L/kg.

Metabolism:

Fampridine is metabolized by oxidation to 3-hydroxy-4-aminopyridine and further conjugated to the 3- hydroxy-4-aminopyridine sulfate. No pharmacological activity was found for the fampridine metabolites against selected potassium channels in vitro.

In vitro studies with human liver microsomes indicate that CYP2E1 was the major enzyme responsible for the 3-hydroxylation of fampridine based on correlation analysis, chemical inhibition studies and incubations with recombinant human CYP enzymes. The identity of the CYP enzymes suspected of playing a minor role in the 3-hydroxylation of fampridine could not be established unequivocally.

Elimination:

Fampridine and metabolites are eliminated nearly complete after 24 hours with 95.85% of the dose recovered in the urine and 0.51% recovery in feces. Most of the excreted radioactivity in the 0-4 hour pooled urine was parent drug (90.3%). Two metabolites were identified: 3-

hydroxy-4-aminopyridine (4.3%) and 3-hydroxy-4-aminopyridine sulfate (2.6%).

The elimination half-life of fampridine following administration of the extended-release tablet formulation of FAMPYRA is 5.2 to 6.5 hours. The plasma half-life of the sulfate conjugate is approximately 7.6 hours and the half-life of 3-hydroxy-4-aminopyridine could not be calculated because concentrations for most subjects were close to or below the limit of quantitation.

Special Populations and Conditions

- **Pediatrics:** The pharmacokinetics of fampridine in the pediatric population has not been studied. FAMPYRA is not indicated for patients younger than 18 years of age
- **Geriatrics:** Clinical studies of FAMPYRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Because FAMPYRA is primarily excreted unchanged by the kidneys, and creatinine clearance decreases with age, monitoring of renal function in elderly patients is recommended (see 7.1 WARNINGS AND PRECAUTIONS, Renal and Special Populations).
- **Sex:** A population pharmacokinetic analysis suggested that female patients would be expected to have higher maximum fampridine plasma concentration than male patients. The magnitude of these relationships is small and does not necessitate any dose modifications.
- **Ethnic Origin:** There was an insufficient number of non-Caucasians to effectively evaluate the influence of ethnicity.
- **Hepatic Insufficiency:** The pharmacokinetics of fampridine have not been studied in subjects with hepatic impairment. Since fampridine is primarily excreted unchanged in the urine, hepatic insufficiency is not expected to significantly affect fampridine pharmacokinetics or recommended dosing.
- **Renal Insufficiency:** The pharmacokinetics of fampridine was studied in 9 male and 11 female subjects with varying degrees of renal function. Elimination of the drug is significantly correlated with the creatinine clearance. Total body clearance of fampridine was reduced in patients with impaired renal function by 42.7% in mild (CLcr \geq 50-80 mL/min), 50.3% in moderate (CLcr = 30-50 mL/min), and 72.7% in severe (CLcr \leq 30 mL/min). The terminal half-life of fampridine is prolonged by 3.3-fold in severe renal impairment but not prolonged in mild or moderate impairment.

Fampridine is contraindicated in patients with renal impairment (see 2 CONTRAINDICATIONS).

11 STORAGE, STABILITY AND DISPOSAL

Store FAMPYRA (fampridine) extended release tablets between 15 to 30° C in the original bottle to protect from light and moisture.

12 SPECIAL HANDLING INSTRUCTIONS


Not applicable

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: fampridine
Chemical name: 4-aminopyridine
Molecular formula: C₅H₆N₂
Molecular mass: 94.1 g/mol
Structural formula:



Physicochemical properties:

Physical Form: Fine white powder

Solubility: At ambient temperature, fampridine is soluble in water, methanol, acetone, tetrahydrofuran, isopropanol, acetonitrile, *N, N*-dimethylformamide, dimethylsulfoxide and ethanol.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Table 5 - Summary of patient demographics for clinical trials in patients with multiple sclerosis

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
MS-F203	Randomized, placebo-controlled, parallel group	Extended-release tablets, Oral, 10 mg BID 21-week study	300*	51.4 (26-70)	Female: 205 (68%) Male: 95 (32%)

MS-F204	Randomized, placebo-controlled, parallel group	Extended-release tablets, Oral, 10 mg BID 14-week study	239	51.7 (24-73)	Female: 162 (68%) Male: 77 (32%)
---------	--	--	-----	-----------------	---

* In study MS-F203, 301 patients were randomized but 1 patient did not take the drug.

14.2 Study Results

Studies MS-F203 and MS-F204

The primary endpoint in studies MS-F203 and MS-F204 was the responder rate in walking speed as measured by the Timed 25-foot Walk (T25FW). A responder was defined as a patient who consistently had a faster walking speed for at least three visits out of a possible four during the double blind period as compared to the maximum value among five off-treatment visits.

A significantly greater proportion of Fampyra treated patients were responders as compared to placebo (MS-F203: 34.8% vs. 8.3%, $p < 0.001$; MS-F204: 42.9% vs. 9.3%, $p < 0.001$).

Patients who responded to Fampyra increased their walking speed on average by 26.3% vs 5.3% on placebo ($p < 0.001$) (MS-F203) and 25.3% vs 7.8% ($p < 0.001$) (MS-F204). The improvement appeared rapidly (within weeks) after starting Fampyra.

Statistically and clinically meaningful improvements in walking were seen, as measured by the 12- item Multiple Sclerosis Walking Scale.

Table 6 - Results of study MS-F203 & MS-F204 in patients with multiple sclerosis

STUDY *	MS-F203		MS-F204	
	Placebo	Fampyra 10 mg BID	Placebo	Fampyra 10 mg BID
n of subjects	72	224	118	119
Consistent improvement	8.3%	34.8%	9.3%	42.9%
Difference		26.5%		33.5%
CI _{95%}		17.6%, 35.4%		23.2%, 43.9%
P-value		< 0.001		< 0.001
≥20% improvement	11.1%	31.7%	15.3%	34.5%

STUDY *	MS-F203		MS-F204	
	Placebo	Fampyra 10 mg BID	Placebo	Fampyra 10 mg BID
Difference		20.6%		19.2%
CI _{95%}		11.1%,30.1%		8.5%,29.9%
P-value		<0.001		<0.001
Walking speed Feet/sec	Ft per sec	Ft per sec	Ft per sec	Ft per sec
Baseline	2.04	2.02	2.21	2.12
Endpoint	2.15	2.32	2.39	2.43
Change	0.11	0.30	0.18	0.31
Difference		0.19		0.12
p-value		0.010		0.038
Average % Change	5.24	13.88	7.74	14.36
Difference		8.65		6.62
p-value		< 0.001		0.007
MSWS-12-score (mean, sem)				
Baseline	69.27 (2.22)	71.06 (1.34)	67.03 (1.90)	73.81 (1.87)
Average change	-0.01 (1.46)	-2.84 (0.878)	0.87 (1.22)	-2.77 (1.20)
Difference		2.83		3.65
p-value		0.084		0.021
LEMMT (mean, sem) (Lower Extremity Manual Muscle Test)				
Baseline	3.92 (0.070)	4.01 (0.042)	4.01 (0.054)	3.95 (0.053)
Average change	0.05 (0.024)	0.13 (0.014)	0.05 (0.024)	0.10 (0.024)
Difference		0.08		0.05
p-value		0.003		0.106
Ashworth Score (A test for muscle				

STUDY *	MS-F203		MS-F204	
	Placebo	Fampyra 10 mg BID	Placebo	Fampyra 10 mg BID
spasticity)				
Baseline	0.98 (0.078)	0.95 (0.047)	0.79 (0.058)	0.87 (0.057)
Average change	-0.09 (0.037)	-0.18 (0.022)	-0.07 (0.033)	-0.17 (0.032)
Difference	0.10		0.10	
p-value	0.021		0.015	

*Consistent improvement: The primary measure of efficacy in both trials was walking speed (in feet per second) as measured by the Timed 25-foot Walk (T25FW), using a responder analysis. A responder was defined as a patient who showed faster walking speed for at least three visits out of a possible four during the double-blind period than the maximum value achieved in the five non-double-blind no treatment visits (four before the double-blind period and one after).

Study 218MS305

Study 218MS305 was conducted in 636 subjects with multiple sclerosis and walking disability. Duration of double-blind treatment was 24 weeks with a 2 week post-treatment follow-up. The primary endpoint was improvement in walking ability, measured as the proportion of patients achieving a mean improvement of ≥ 8 points from baseline MSWS-12 score over 24 weeks. In this study there was a statistically significant treatment difference, with a greater proportion of Fampyra treated patients demonstrating an improvement in walking ability, compared to placebo-controlled patients (relative risk of 1.38 (95% CI: [1.06, 1.70])). Improvements generally appeared within 2 to 4 weeks of initiation of treatment, and disappeared within 2 weeks of treatment cessation.

Fampyra treated patients also demonstrated a statistically significant improvement in the Timed Up and Go (TUG) test, a measure of static and dynamic balance and physical mobility. In this secondary endpoint, a greater proportion of Fampyra treated patients achieved $\geq 15\%$ mean improvement from baseline TUG speed over a 24 week period, compared to placebo. The difference in the Berg Balance Scale (BBS; a measure of static balance), was not statistically significant.

The Least Squares (LS) mean change from baseline to double-blind on-treatment MSWS-12 score showed a greater improvement in subjects treated with prolonged-release fampridine (-6.73 ; 95% CI: $[-8.80, -4.67]$) compared with subjects treated with placebo (-2.59 ; 95% CI: $[-4.71, -0.47]$). The LS mean difference between the groups was -4.14 (95% CI: $-6.22, -2.06$); $p < 0.001$; in favor of prolonged-release fampridine.

In addition, patients treated with Fampyra demonstrated a statistically significant mean improvement from baseline compared to placebo in the Multiple Sclerosis Impact Scale (MSIS-29) physical score (LSM difference -3.31 , $p < 0.001$).

Table 7: Primary and key secondary endpoints of study 218MS305

Over 24 weeks	Placebo N = 318*	Fampyra 10 mg BID N = 315*	Difference (95% CI) p - value
MSWS-12 score Proportion of patients with mean improvement of ≥ 8 points from baseline MSWS-12 score	34%	43%	Risk difference: 10.4% (3% ; 17.8%) 0.006
TUG Proportion of patients with mean improvement of $\geq 15\%$ in TUG speed	35%	43%	Risk difference: 9.2% (0.9% ; 17.5%) 0.03
MSIS-29 physical score Baseline Improvement from baseline	55.3 -4.68	52.4 -8.00	LSM: -3.31 (-5.13 ; -1.50) <0.001

*Intent to treat population = 633; LSM = Least square mean

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology: The preclinical safety of 4-AP was assessed in mice, rats, rabbits and dogs. The dosing regimen greatly affected the rate of mortality and incidence of adverse clinical signs in all species studied. In general, higher rates of mortality and adverse clinical signs were noted when 4-AP was administered in a single large dose as compared to administration by multiple (two, three, or four) equally divided sub-doses, or when administered through dietary admixture. This suggested that peak plasma levels may be more important than total exposure when considering toxicity of 4-AP.

Toxic responses to orally administered 4-AP were rapid in onset and included tremors, convulsions, ataxia, dyspnea, dilated pupils, prostration, abnormal vocalization, increased respiration, excess salivation, gait abnormalities, and hyper- and hypo-excitability. These clinical signs were not unexpected and represent exaggerated pharmacology of 4-AP. In single-dose studies in rats and in repeated-dose studies in dogs, gross necropsy findings

observed in animals that died prematurely included discolorations of the kidney, lung and liver, thymus and spleen. In a 1 year repeated-dose study in dogs, these lesions were evaluated histologically, and were characterized as congestion and hemorrhage secondary to convulsion. In repeated-dose studies, no histological evidence of target organ toxicity was observed in either rats or dogs that survived to scheduled termination, aside from glandular dilation of the stomach in treated rats. Exposures associated with the no adverse effect levels (NOAEL) in these species were between 2- (rat, glandular dilation of the stomach) and 10-fold above those achieved in humans at the MRHD of 10 mg administered twice daily (b.i.d).

Carcinogenicity: No evidence of carcinogenicity was observed in either of the 2-year bioassays conducted in mice and rats when administered via dietary admixture, at the maximally tolerated doses of 80 and 18 mg/kg/day, respectively. In mice receiving 80 mg/kg/day, mean plasma exposures in males were approximately 17-fold above the anticipated peak clinical exposure of 21.6 ng/mL at the MRHD of 10 mg b.i.d. Mean exposures in surviving females, euthanized during week 100 due to reduced survival at the 80 mg/kg/day dose level, were approximately 11-fold above the anticipated peak clinical exposure at the MRHD of 10 mg b.i.d.

Similar exposures were obtained during the 104-week carcinogenicity study in rats. Mean exposures in males at the 18 mg/kg/day dose level were approximately 17-fold above the peak exposure of 21.6 ng/mL at the MRHD of 10 mg b.i.d, and approximately 12-fold in females. A slight, non-dose-related increase in uterine polyps was observed in female rats at 18 mg/kg/day. Microscopically, an increased incidence of inflammation of the foot with secondary reaction in the regional lymph nodes and hypercellularity of the bone marrow was seen, particularly at 18 mg/kg/day.

Genotoxicity: 4-Aminopyridine was not mutagenic in either the Ames bacterial mutagenicity test or in the L5178Y mouse lymphoma cell line, when tested *in vitro*. No clastogenic effects were observed either *in vitro*, when tested in Chinese Hamster Ovary (CHO) cells or *in vivo*, when tested in mice at oral doses of 9 mg/kg, or in Sprague Dawley rats at oral doses of 15 mg/kg.

Reproductive and Developmental Toxicology: No adverse effects were noted on fertility or copulatory indices in rats, and no treatment-related variations in estrous cyclicity, were attributed to 4-aminopyridine in surviving animals at doses of up to 9 mg/kg. There were no indications of developmental toxicity and no test article-related fetal malformations or developmental variations at any dosage level tested when pregnant dams were exposed to oral doses of up to 10 mg/kg/day (rat) or 5 mg/kg/day (rabbit) during the period of fetal organogenesis. Based upon data from bridging toxicokinetic studies, peak plasma exposures in pregnant rats and rabbits were greater than 23-fold above those achieved in humans at the MRHD of 10 mg b.i.d.

Effects on parturition and lactation, as evidenced from neonatal behavior, viability, growth and offspring (F1) reproductive performance, were evaluated in rats at doses of up to 6 mg/kg/day. Doses of 3 and 6 mg/kg/day were maternally toxic, as evidenced by reduced maternal food consumption and body weight during both gestation and lactation, and fewer live births were observed in pregnant dams in the 6 mg/kg dose group. Administration of 4-AP to offspring

(F1) through lactation also resulted in fewer live pups per litter and reduced weight gain during and beyond lactation for animals in the 6 mg/kg dose group; however, no effects were observed at any dose level, with respect to behavior and development. Based up on data from a bridging toxicokinetic study, peak exposure levels in lactating dams were greater than 28-fold above those achieved in humans at the MRHD of 10 mg b.i.d.

Secretion of fampridine in milk has not been studied in animals.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **FAMPYRA™**

Fampridine extended-release tablets

Read this carefully before you start taking **FAMPYRA** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **FAMPYRA**.

What is FAMPYRA used for?

FAMPYRA is used to improve walking in adults with Multiple Sclerosis (MS) related walking disability.

How does FAMPYRA work?

In MS, inflammation destroys the protective layer around the nerves. This leads to muscle weakness, muscle stiffness and difficulty walking.

FAMPYRA contains the active substance fampridine, which belongs to a group of medicines called potassium channel blockers. It works by stopping potassium leaving the nerve cells which have been damaged by MS. FAMPYRA is thought to work by letting signals pass down the nerve more normally, which allows you to walk better.

What are the ingredients in FAMPYRA?

Medicinal ingredients: fampridine

Non-medicinal ingredients: colloidal silicon dioxide, hypromellose, macrogol/PEG 400, magnesium stearate, microcrystalline cellulose, and titanium dioxide.

FAMPYRA comes in the following dosage forms:

Extended-Release tablets: 10 mg

Do not use FAMPYRA if:

- you are allergic to fampridine or any of the other ingredients in FAMPYRA or its packaging.
- you are taking 4-aminopyridine (4-AP) compounded by your pharmacist.
- you are taking any other medicine containing fampridine. This may increase your risk of

serious side effects.

- your healthcare professional has told you that you have moderate or severe kidney problems
- you have a seizure or ever had a seizure (also referred to as a fit or convulsion).
- you are taking medicines that will reduce the elimination of FAMPYRA from your body, which may increase your risk of serious side effects. Some of these medicines include cimetidine, and quinidine.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take FAMPYRA. Talk about any health conditions or problems you may have, including if you:

- have any factors or are taking any medicines which affect your risk of seizures.
- have heart rhythm or conduction problems.
- are prone to infections.
- use a walking aid, such as a cane. FAMPYRA may make you feel dizzy or unsteady and may increase your risk of falling. If you use a walking aid, you should continue to use it as needed.
- have a history of nerve pain in the face (trigeminal neuralgia). FAMPYRA may make your condition worse.
- are taking medicines that may affect your kidney function, such as:
 - beta blockers, which are medicines used to treat high blood pressure such as carvedilol, pindolol, or propranolol.
 - procainamide, a medicine used to treat abnormal heart rhythms.
 - metformin, a medicine used to treat type 2 diabetes.
 - ranitidine, a medicine used to treat ulcers of the stomach or intestines.
 - varenicline, a medicine used to help you stop smoking.

Other warnings you should know about:

FAMPYRA can cause serious side effects, including:

- **Seizures (fits):** Your risk of seizures increases when you take FAMPYRA, especially if you:
 - take more than the prescribed dose of FAMPYRA.
 - do not take FAMPYRA as prescribed.
 - take certain medicines at the same time (e.g. bupropion, tramadol, tapentadol, or preparations used for colon cleansing).
 - have kidney problems or other factors that increases your risk of seizures as determined by a healthcare professional.
- **Allergic reactions:** Serious allergic reactions have been observed in patients treated with FAMPYRA. Symptoms included rash, itching, difficulty breathing, swelling of the face, lips, tongue or throat. In several cases, these reactions occurred after the first

dose. If you experience an allergic reaction, **stop** taking FAMPYRA and tell your healthcare professional **right away**.

See the **Serious side effects and what to do about them** table, below, for more information on these and other serious side effects.

Urinary tract infection (UTI): An increase in UTIs has been noted in patients taking FAMPYRA. If you experience signs of a UTI, such as difficult or painful urination, bladder pain, or abdominal pain, tell your healthcare professional **right away**.

Infection: FAMPYRA may reduce the number of cells that fight infection in the body (white blood cells). This can make you more likely to get an infection. Tell your healthcare professional **right away** if you notice signs of an infection, such as fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or apathy.

Driving and using machines: FAMPYRA may cause dizziness, balance problems, or fatigue. You should not drive or use tools or machinery until you know how you respond to FAMPYRA.

Pregnancy: FAMPYRA is not recommended during pregnancy. If you become pregnant or think you are pregnant while taking FAMPYRA, contact your healthcare professional **right away**. Your healthcare professional will consider the benefit of you being treated with FAMPYRA against the risk to your baby.

Breast-feeding: It is not known if FAMPYRA can pass into breast milk and harm your baby. Therefore, FAMPYRA should not be used during breast-feeding. Talk to your healthcare professional about ways to feed your baby while taking FAMPYRA.

Check-ups and testing:

- Your healthcare professional will evaluate your risk of seizures before you are prescribed FAMPYRA. They will tell you if it is right for you.
- Your healthcare professional will assess your walking ability before you start FAMPYRA and within the first 4 weeks of treatment. If you and your healthcare professional decide there has not been any improvements during this period, the treatment will be stopped. If the decision is to continue treatment, you and your healthcare professional will continue to regularly monitor your walking ability. Your treatment will be stopped if you are not experiencing any benefit.
- Your healthcare professional may also do blood tests before you start FAMPYRA and regularly during treatment. This is to check if your kidneys are working properly.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with FAMPYRA:

- other medicines containing fampridine.
- 4-aminopyridine (4-AP), a medicine compounded by a pharmacist that manages some of the symptoms of MS, and improves the ability to walk in adults.

- medicines that will reduce the elimination of FAMPYRA from your body, such as cimetidine, and quinidine.
- medicines that may affect your kidney function, such as:
 - beta blockers, which are medicines used to treat high blood pressure such as carvedilol, pindolol, or propranolol.
 - procainamide, a medicine used to treat abnormal heart rhythms.
 - metformin, a medicine used to treat type 2 diabetes.
 - ranitidine, a medicine used to treat ulcers of the stomach or intestines.
 - varenicline, a medicine used to help you stop smoking.
- medicines that may affect your risk of seizures, such as bupropion, tramadol, tapentadol, or preparations used for colon cleansing.

Ask your healthcare professional if you are not sure whether the medicines you take are in the list above.

How to take FAMPYRA:

- Take FAMPYRA exactly as your healthcare professional tells you. Do not take more than the prescribed dose.
- Take FAMPYRA without food.
- Swallow tablet whole, with a drink of water. If you cannot swallow FAMPYRA tablets whole, tell your healthcare professional.
- Do not divide, crush, dissolve, suck or chew the tablet. A broken tablet can release too much of the medicine at one time. This can increase your risk of having a seizure.

Usual dose:

Take one 10 mg tablet of FAMPYRA in the morning and one 10 mg tablet in the evening. **You must leave 12 hours between each tablet. Do not take a tablet more often than every 12 hours.**

Overdose:

Symptoms of an overdose include:

- confusion
- excessive sweating
- seizures
- memory loss (amnesia)
- involuntary movements, shaking or twitching
- abnormal heart rhythms
- high blood pressure

If you think you, or a person you are caring for, have taken too much FAMPYRA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you forget or miss a dose of FAMPYRA, skip the missed dose and take the next dose as scheduled. **Do not double the dose to make up for the missed dose.** You must always leave 12 hours between each tablet. Taking more than your prescribed dose can increase your risk of experiencing serious side effects.

What are possible side effects from using FAMPYRA?

These are not all the possible side effects you may feel when taking FAMPYRA. If you experience any side effects not listed here, tell your healthcare professional.

Very common side effects:

- Urinary tract infection

Common side effects:

- feeling unsteady
- dizziness
- headache
- feeling weak and tired
- difficulty sleeping
- anxiety
- tremor (minor shaking)
- numbness or tingling of the skin
- sore throat
- feeling sick (nausea)
- being sick (vomiting)
- constipation
- upset stomach
- back pain
- Vertigo

Uncommon side effects:

- Worsening of nerve pain in the face (trigeminal neuralgia)

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Dyspnea (shortness of breath)			√
RARE			
Seizures (fits): loss of consciousness with uncontrollable shaking			√
Allergic reaction: difficulty swallowing or breathing, wheezing; drop in blood pressure; feeling sick to your stomach and throwing up; hives or rash; swelling of the face, lips, tongue or throat.			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store FAMPYRA at room temperature (between 15 to 30 °C).
- Store the tablets in the original bottle to protect from light and moisture.
- Discard your medicine after the expiry date shown on the packaging.
- Keep out of reach and sight of children.

If you want more information about FAMPYRA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the Biogen Canada Inc.'s website (<https://www.biogen.ca>), or by calling 1-855-676-6300.

This leaflet was prepared by Biogen Canada Inc.

Last Revised JAN 24, 2022

FAMPYRA™ is marketed under license from Acorda Therapeutics, Inc. and is manufactured for Acorda under license from Alkermes Pharma Ireland Limited (APIL). FAMPYRA™ is a trademark of Acorda Therapeutics, Inc.

© Biogen [2012]. All rights reserved.